APA (7th ed.) Citation

H, Z., Y, D., Y, G., D, F., NTT, H., E, M., . . . L, Z. (2026). Dihydromyricetin: A potential candidate for the treatment of cholestatic liver injury via inhibition of the NLRP3 inflammasome. European journal of pharmacology, 1025, 178928. https://doi.org/10.1016/j.ejphar.2026.178928

Chicago Style (17th ed.) Citation

H, Zhang, et al. "Dihydromyricetin: A Potential Candidate for the Treatment of Cholestatic Liver Injury via Inhibition of the NLRP3 Inflammasome." European Journal of Pharmacology 1025 (2026): 178928. https://doi.org/10.1016/j.ejphar.2026.178928.

MLA (9th ed.) Citation

H, Zhang, et al. "Dihydromyricetin: A Potential Candidate for the Treatment of Cholestatic Liver Injury via Inhibition of the NLRP3 Inflammasome." European Journal of Pharmacology, vol. 1025, 2026, p. 178928, https://doi.org/10.1016/j.ejphar.2026.178928.